ARNA · Arena Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Revenue | $54.0K | $319.0K | $92.16M | $21.34M | $123.97M | $38.33M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $323.74M | $323.74M | $115.03M | $70.99M | $66.42M | $88.41M |
| SG&A | $126.21M | $103.22M | $47.72M | $30.34M | $31.24M | $35.97M |
| Total Operating Expenses | $624.35M | $426.96M | $162.75M | $113.30M | $141.12M | $141.52M |
| D&A | $3.87M | $3.86M | $3.76M | $4.28M | $9.14M | $9.80M |
| Operating Income | ($624.30M) | ($426.64M) | ($144.78M) | ($91.97M) | ($17.15M) | ($103.20M) |
| Interest Expense | $4.16M | $4.52M | $5.70M | $6.12M | $6.51M | $6.83M |
| Income Tax | $0 | $0 | ($110.27M) | $0 | $0 | $0 |
| Net Income | ($616.43M) | ($404.73M) | ($29.40M) | ($91.41M) | ($22.52M) | ($107.98M) |
| EPS - Basic | ($10.14) | ($7.39) | - | - | ($0.09) | ($0.45) |
| EPS - Diluted | ($10.14) | ($7.39) | - | - | ($0.09) | ($0.45) |
Balance Sheet
| Line item | FY 2021 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $224.57M | $219.54M | $161.04M | $158.84M | $90.71M | $156.18M |
| Accounts Receivable | - | $1.65M | $5.09M | $2.36M | $20.16M | $4.93M |
| Inventory | - | - | - | - | $6.71M | $9.50M |
| Accounts Payable | $13.30M | $12.00M | $6.19M | $1.60M | $5.98M | $2.08M |
| Current Assets | $569.47M | $1.14B | $460.73M | $281.28M | $119.89M | $174.84M |
| Total Assets | $784.71M | $1.19B | $686.90M | $339.27M | $169.01M | $256.79M |
| Current Liabilities | $66.32M | $58.08M | $29.92M | $72.33M | $63.88M | $49.90M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $673.24M | $1.08B | $606.26M | $207.14M | $39.90M | $53.54M |
| Retained Earnings | ($2.12B) | ($1.51B) | ($1.50B) | ($1.49B) | ($1.40B) | ($1.38B) |
Cash Flow
| Line item | FY 2021 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($452.02M) | ($353.09M) | ($132.21M) | ($62.14M) | ($62.14M) | ($101.40M) |
| Investing Cash Flow | $321.40M | ($21.40M) | ($251.27M) | ($750.0K) | ($750.0K) | $40.90M |
| Financing Cash Flow | $135.41M | $350.61M | $385.03M | ($2.29M) | ($2.29M) | $3.17M |
| CapEx | $988.0K | $820.0K | $692.0K | $113.0K | $950.0K | $10.99M |
| Free Cash Flow | ($453.00M) | ($353.91M) | ($132.90M) | ($62.25M) | ($63.09M) | ($112.39M) |
Ratios
| Metric | FY 2021 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -1156109.3% | -133742.6% | -157.1% | -431.0% | -13.8% | -269.3% |
| EBITDA margin | -1148938.9% | -132533.2% | -153.0% | -411.0% | -6.5% | -243.7% |
| Net margin | -1141542.6% | -126875.9% | -31.9% | -428.4% | -18.2% | -281.7% |
| Free cash flow margin | -838896.3% | -110944.8% | -144.2% | -291.8% | -50.9% | -293.2% |
| FCF / Net income | 0.73 | 0.87 | 4.52 | 0.68 | 2.80 | 1.04 |
| R&D / Revenue | 599518.5% | 101485.9% | 124.8% | 332.7% | 53.6% | 230.7% |
| SG&A / Revenue | 233714.8% | 32356.7% | 51.8% | 142.2% | 25.2% | 93.8% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -78.6% | -34.0% | -4.3% | -26.9% | -13.3% | -42.0% |
| Return on equity | -91.6% | -37.5% | -4.8% | -44.1% | -56.4% | -201.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 8.59 | 19.62 | 15.40 | 3.89 | 1.88 | 3.50 |
| Quick ratio | 8.59 | 19.62 | 15.40 | 3.89 | 1.77 | 3.31 |
| Cash ratio | 3.39 | 3.78 | 5.38 | 2.20 | 1.42 | 3.13 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -150.1x | -94.3x | -25.4x | -15.0x | -2.6x | -15.1x |
| Equity multiplier | 1.17 | 1.10 | 1.13 | 1.64 | 4.24 | 4.80 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.00 | 0.13 | 0.06 | 0.73 | 0.15 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | 1893d | 20d | 40d | 59d | 47d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | -99.7% | 331.9% | -82.8% | 223.5% | 3.7% |
| Revenue CAGR (3y) | -91.6% | -86.3% | 34.0% | -16.7% | 15.1% | 11.6% |
| Revenue CAGR (5y) | -78.7% | -61.3% | 2.5% | -5.0% | 64.2% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -194.7% | -57.4% | -436.4% | 83.4% | 2.0% |
| Net income growth (YoY) | - | -1276.7% | 67.8% | -306.0% | 79.1% | -78.5% |
| EPS growth (YoY) | - | - | - | - | 80.0% | -60.7% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | -166.3% | -113.5% | 1.3% | 43.9% | -112.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | 78.2% | 192.7% | 419.1% | -25.5% | 13.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$54.0K totalCollaboration And Other Revenue$54.0K · 100.0%
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- -ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ARENA PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.